Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma

American Journal of Hematology

Volumn 85, Issue 10, 2010, Pages 822-824

  Kim, Hee Nam ^a   Yu, Li ^a   Kim, Nan Young ^a   Lee, Il Kwon ^a   Kim, Yeo Kyeoung ^b   Yang, Deok Hwan ^b   Lee, Je Jung ^b   Shin, Min Ho ^c   Park, Kyeong Soo ^d   Choi, Jin Su ^c   Kim, Hyeoung Joon ^a,b  

^a Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^b Chonnam National University   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d Seonam University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; CODON; TP53 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CODON; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENOTYPE; HUMAN; KOREA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH KOREA; TUMOR SUPPRESSOR GENE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CODON; FEMALE; GENE FREQUENCY; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REPUBLIC OF KOREA; RISK; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 77957677427     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21834     Document Type: Article

References (28)

1. Lung FW, Shu BC, Kao WT, et al. Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: A case-control study. BMC Med Genet 2009;10:147.
2. Zhuo W, Zhang Y, Xiang Z, et al. Polymorphisms of TP53 codon 72 with breast carcinoma risk: Evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res 2009;28:115.
3. Fernandez-Rubio A, Lopez-Cima MF, Gonzalez-Arriaga P, et al. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer 2008;61:309-316.
4. Boltze C, Roessner A, Landt O, et al. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol 2002;21:1151-1154.
5. Hishida A, Matsuo K, Tajima K, et al. Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk Lymphoma 2004;45:957-964. (Pubitemid 38444672)
6. Takeuchi S, Matsushita M, Tsukasaki K, et al. P53 codon 72 polymorphism is associated with disease progression in adult T-cell leukaemia/lymphoma. Br J Haematol 2005;131:552-553.
7. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
8. Harris SL, Levine AJ. The p53 pathway: Positive and negative feedback loops. Oncogene 2005;24:2899-2908.
9. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
10. Khan SA, Thomas HC, Toledano MB, et al. p53 Mutations in human cholangiocarcinoma: A review. Liver Int 2005;25:704-716. (Pubitemid 41038651)
11. Bumroongkit K, Rannala B, Traisathit P, et al. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors. Cancer Genet Cytogenet 2008;185:20-27. (Pubitemid 352010359)
12. Assumpcao JG, Seidinger AL, Mastellaro MJ, et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 2008;8:357.
13. Harris N, Brill E, Shohat O, et al. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 1986;6:4650-4656.
14. Sengupta S, Harris CC. p53: Traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005;6:44-55.
15. Dumont P, Leu JI, Della Pietra AC, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-365.
16. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-199. (Pubitemid 37541770)
17. Xiong X, Wang M, Wang L, et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res 2009;33:1454-1458.
18. Zhang W, Hu G, Deisseroth A. Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene 1992;117:271-275.
19. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008;112:741-749.
20. Bergamaschi G, Merante S, Orlandi E, et al. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 2004;89:868-869. (Pubitemid 38981351)
21. Kochethu G, Delgado J, Pepper C, et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res 2006;30:1113-1118. (Pubitemid 44037084)
22. Lung FW, Lee TM, Shu BC, et al. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 2004;130:728-732.
23. Jones JS, Chi X, Gu X, et al. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004;10:5845-5849. (Pubitemid 39180964)
24. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: A systematic review and meta-analysis. Mutagenesis 2003;18:377-385.
25. Preudhomme C, Fenaux P. The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Br J Haematol 1997;98:502-511.
26. Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002;21:3475-3495. (Pubitemid 34587717)
27. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
28. Kim HN, Lee IK, Kim YK, et al. Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma. Br J Haematol 2008;140:287-294.